What Olivia Hussey's Story Can Help Us Understand About Breast Cancer

Ten years between two dates

Variety reported that Olivia Hussey Eisley, who played Juliet in Franco Zeffirelli's 1968 Romeo and Juliet, died on December 27, 2024. She was 73.

Her death was confirmed to the San Francisco Chronicle by the filmmaker Marc Huestis, who said she died of cancer, and announced on her Instagram account. Her family's statement said she went peacefully at home, surrounded by loved ones.

Variety records two dates from her medical history. She was diagnosed with breast cancer in 2008. The cancer returned in 2018.

That gap is the part of her story that carries the most useful information, and it is the part usually skipped.

Why ten years is not unusual

Most people assume that if a cancer has not come back within five years, it is gone. For some breast cancers that is broadly true. For others it is not.

Hormone receptor-positive breast cancer, the most common kind, can come back long after treatment ends. The evidence for this is buried in a place people rarely look: trials of how long to keep taking hormone-blocking tablets.

The ATLAS trial randomly assigned 12,894 women with early breast cancer to 10 years of tamoxifen or 5 years. Ten years reduced recurrences, breast cancer deaths and deaths from any cause.

Tucked into NCI's summary of that trial is a sentence that says everything. Counting from the original diagnosis, the benefit of the longer course was smaller before year 10 than after it.

In other words, the risk that a longer course was protecting against was still arriving in the second decade. Our page on hormone therapy for breast cancer covers what those tablets do and what taking them for a decade is like.

What a recurrence is, and is not

A recurrence means the original cancer has returned. It can come back in the same breast or the chest wall, in nearby lymph nodes, or somewhere distant such as bone, liver, lung or brain.

That last kind is metastatic breast cancer. It is the same disease that started in the breast, not a new cancer of the bone or liver, and it is treated as breast cancer.

A separate new cancer in the other breast is a different event with a different meaning. Telling these apart takes imaging and usually a biopsy, because the treatment plan follows from which one it is.

Our pages on what to ask about recurrence and on metastatic breast cancer cover the conversations that follow each.

When to get checked

NCI is direct that early breast cancer often has no symptoms at all, which is why screening exists alongside any symptom list.

The changes NCI says to bring to a doctor:

• A lump in or near the breast, or under the arm.
• A thick or firm area in either place.
• A change in the size or shape of a breast.
• Fluid or discharge from the nipple that is not breast milk.
• A nipple that changes shape, flattens, or points in a different direction.
• Scaly or swollen skin, redness or darkening, or itching on the breast, nipple or areola.

For people with no symptoms, the U.S. Preventive Services Task Force recommends a mammogram every two years for women aged 40 to 74. Our page on mammograms covers what the appointment involves.

Anyone treated for breast cancer in the past has a third track: follow-up appointments that continue for years, and a low threshold for reporting new bone pain, a persistent cough, or unexplained weight loss.

The group picture

SEER figures describe the United States population, not any individual.

Five-year relative survival for female breast cancer is 91.9 percent for cases from 2016 to 2022. By stage it is 100.0 percent while confined to the breast, 87.5 percent once it reaches nearby lymph nodes, and 33.8 percent once it has spread further.

Sixty-four percent are found at that first stage. An estimated 321,910 new cases and 42,140 deaths are projected for 2026, and the median age at diagnosis is 64.

What this does not mean

Sixteen years between diagnosis and death is not a prediction for anyone else. It is one person's course, shaped by her tumor biology, her stage, her treatment and her general health.

Nor does a late recurrence mean the first treatment failed. Breast cancer that returns after a decade is a known feature of some subtypes, not evidence that something was missed.

And the five-year mark is a statistical convention, not a finish line. It is the point at which survival is conventionally measured. It is not the point at which risk becomes zero, and for hormone receptor-positive disease it clearly is not.

That is the useful thing to carry from her story. Follow-up after breast cancer is long for a reason.

Sources

• Variety, Olivia Hussey, 'Romeo and Juliet' and 'Black Christmas' Star, Dies at 73 — https://variety.com/2024/film/obituaries-people-news/olivia-hussey-dead-romeo-and-juliet-black-christmas-1236261093/
• Variety, Olivia Hussey, 'Romeo and Juliet' Star, Dies at 73 — https://variety.com/2024/film/news/olivia-hussey-dead-romeo-and-juliet-1236260306/
• NCI, Breast Cancer Signs and Symptoms — https://www.cancer.gov/types/breast/symptoms
• NCI PDQ, Breast Cancer Treatment (Health Professional Version) — https://www.cancer.gov/types/breast/hp/breast-treatment-pdq
• SEER Cancer Stat Facts, Female Breast Cancer — https://seer.cancer.gov/statfacts/html/breast.html
• USPSTF, Breast Cancer: Screening — https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.